MacroGenics, Inc.
9704 Medical Center Drive
Rockville
Maryland
20850
United States
216 articles with MacroGenics, Inc.
-
MacroGenics Provides Update on Corporate Progress and First Quarter 2022 Financial Results
5/3/2022
MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the quarter ended March 31, 2022.
-
MacroGenics Announces Date of First Quarter 2022 Financial Results Conference Call
4/25/2022
MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the first quarter 2022 after the market closes on Tuesday, May 3, 2022.
-
MacroGenics to Participate in Upcoming Investor Conferences in March 2022
3/3/2022
MacroGenics, Inc., a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, announced that the Company's management will participate in the following investor conferences in March 2022:
-
MacroGenics Announces Executive Promotion
2/28/2022
MacroGenics, Inc., a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, announced that it has promoted Eric Risser to Chief Operating Officer, as of February 22.
-
MacroGenics Provides Update on Corporate Progress and 2021 Financial Results
2/24/2022
MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the year ended December 31, 2021.
-
MacroGenics Announces Date of Fourth Quarter 2021 Financial Results Conference Call
2/14/2022
MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the fourth quarter of 2021 after the market closes on Thursday, February 24, 2022.
-
MacroGenics to Participate in Upcoming Investor Conferences - Feb 03, 2022
2/3/2022
MacroGenics, Inc., a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, announced that the Company's management will participate in the following virtual conferences in February 2022.
-
MacroGenics to Participate in Upcoming Investor Conferences - Nov 03, 2021
11/3/2021
MacroGenics, Inc., a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, announced that the Company's management will participate in the following conferences in November and December 2021:
-
MacroGenics Provides Update on Corporate Progress and Third Quarter 2021 Financial Results
11/2/2021
MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the quarter ended September 30, 2021.
-
MacroGenics Announces Date of Third Quarter 2021 Financial Results Conference Call
10/26/2021
MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the third quarter of 2021 after the market closes on Tuesday, November 2, 2021.
-
Clinical Catch-Up: September 13-17
9/20/2021
With a conference the size of ESMO, it’s impossible to cover all the exciting news, but here are many of the highlights. Here’s a look. -
MacroGenics Announces Preliminary Clinical Results from Phase 1 Cohort Expansion of the Ongoing MGC018 Study Presented at ESMO 2021 Virtual Annual Congress
9/16/2021
MacroGenics, Inc., a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, announced preliminary safety and anti-tumor activity data from dose expansion cohorts of the Company’s ongoing Phase 1 clinical trial of MGC018.
-
MacroGenics Announces Clinical Results from Cohort A Part 1 of Phase 2/3 MAHOGANY Study of Margetuximab in Combination with Retifanlimab in Gastroesophageal Adenocarcinoma at ESMO 2021
9/16/2021
MacroGenics, Inc., a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, announced results from Cohort A Part 1 of the Phase 2/3 MAHOGANY clinical trial of margetuximab.
-
MacroGenics Announces Presentations at ESMO 2021 Virtual Annual Congress
9/12/2021
MacroGenics, Inc., a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, announced poster presentations relating to multiple investigational product candidates at the European Society for Medical Oncology Virtual Conference, taking place September 16-21, 2021.
-
The biopharmaceutical company announced the final overall survival analysis of its drug MARGENZA in SOPHIA Phase III study in adults with metastatic breast cancer.
-
MacroGenics Announces Final Overall Survival Results from SOPHIA Study of MARGENZA™ in Patients with HER2-Positive Metastatic Breast Cancer
9/7/2021
MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced the final overall survival (OS) results of the SOPHIA Phase 3 study in adult patients with metastatic HER2-positive breast cancer.
-
MacroGenics to Participate in Upcoming Investor Conferences in September 2021
9/2/2021
MacroGenics, Inc., a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, announced that the Company's management will participate in the following investor conferences in September.
-
MacroGenics to Participate in Upcoming Investor Conferences - Aug 05, 2021
8/5/2021
MacroGenics, Inc., a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, announced that the Company's management will participate in the following conferences in August:
-
MacroGenics Provides Update on Corporate Progress and Second Quarter 2021 Financial Results
7/29/2021
MacroGenics, Inc., a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, provided an update on its recent corporate progress and reported financial results for the quarter ended June 30, 2021.
-
MacroGenics Announces Date of Second Quarter 2021 Financial Results Conference Call
7/22/2021
MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the second quarter 2021 after the market closes on Thursday, July 29, 2021